Your browser doesn't support javascript.
loading
Dopamine-loaded chitosan-coated solid lipid nanoparticles as a promise nanocarriers to the CNS.
Ortega Martínez, Elena; Morales Hernández, Ma Encarnación; Castillo-González, Julia; González-Rey, Elena; Ruiz Martínez, Ma Adolfina.
Afiliação
  • Ortega Martínez E; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071, Granada, Spain.
  • Morales Hernández ME; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071, Granada, Spain. Electronic address: maen@ugr.es.
  • Castillo-González J; Institute of Parasitology and Biomedicine "Lopez-Neyra", CSIC, Avenida del Conocimiento s/n, 18016, Granada, Spain.
  • González-Rey E; Institute of Parasitology and Biomedicine "Lopez-Neyra", CSIC, Avenida del Conocimiento s/n, 18016, Granada, Spain.
  • Ruiz Martínez MA; Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Granada, Campus de Cartuja s/n, 18071, Granada, Spain.
Neuropharmacology ; 249: 109871, 2024 May 15.
Article em En | MEDLINE | ID: mdl-38412889
ABSTRACT
Dopamine is unable to access the central nervous system through the bloodstream. Only its precursor can do so, and with an effectiveness below 100% of the dose administered, as it is metabolized before crossing the blood-brain barrier. In this study, we describe a new solid lipid nanocarrier system designed and developed for dopamine. The nanoparticles were prepared by the melt-emulsification method and then coated with chitosan. The nanocarriers developed had a droplet size of about 250 nm, a polydispersity index of 0.2, a positive surface charge (+30 mV), and a percentage encapsulation efficiency of 36.3 ± 5.4. Transmission and scanning electron microscopy verified uniformity of particle size with spherical morphology. Various types of tests were performed to confirm that the nanoparticles designed are suitable for carrying dopamine through the blood-brain barrier. In vitro tests demonstrated the ability of these nanocarriers to pass through endothelial cell monolayers without affecting their integrity. This study shows that the formulation of dopamine in chitosan-coated solid lipid nanoparticles is a potentially viable formulation strategy to achieve the bioavailability of the drug for the treatment of Parkinson's disease in the central nervous system.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quitosana / Nanopartículas / Lipossomos Idioma: En Revista: Neuropharmacology Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quitosana / Nanopartículas / Lipossomos Idioma: En Revista: Neuropharmacology Ano de publicação: 2024 Tipo de documento: Article